{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lisdexamfetamine+dimesylate+%28LDX%29&page=2",
    "query": {
      "intervention": "Lisdexamfetamine dimesylate (LDX)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 39,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lisdexamfetamine+dimesylate+%28LDX%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lisdexamfetamine+dimesylate+%28LDX%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-12T15:41:29.533Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01552902",
      "title": "Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention-deficit/Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "Lisdexamfetamine dimesylate",
          "type": "DRUG"
        },
        {
          "name": "Methylphenidate Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "13 Years to 17 Years"
      },
      "enrollment_count": 549,
      "start_date": "2012-04-03",
      "completion_date": "2014-05-22",
      "has_results": true,
      "last_update_posted_date": "2021-06-10",
      "last_synced_at": "2026-10-12T15:41:29.533Z",
      "location_count": 81,
      "location_summary": "Dothan, Alabama • Tucson, Arizona • Little Rock, Arkansas + 68 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Colton",
          "state": "California"
        },
        {
          "city": "Imperial",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01552902"
    },
    {
      "nct_id": "NCT01274221",
      "title": "Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "ADHD"
      ],
      "interventions": [
        {
          "name": "SPD489",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "13 Years to 17 Years"
      },
      "enrollment_count": 0,
      "start_date": "2011-03-06",
      "completion_date": "2011-05-04",
      "has_results": false,
      "last_update_posted_date": "2021-06-03",
      "last_synced_at": "2026-10-12T15:41:29.533Z",
      "location_count": 6,
      "location_summary": "Little Rock, Arkansas • Bradenton, Florida • Overland Park, Kansas + 3 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01274221"
    },
    {
      "nct_id": "NCT01760889",
      "title": "SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "SPD489 low dose range (40mg, 80mg, and 100mg)",
          "type": "DRUG"
        },
        {
          "name": "SPD489 high dose range (120mg, 140mg and 160mg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 1,
      "start_date": "2013-02-01",
      "completion_date": "2013-04-01",
      "has_results": true,
      "last_update_posted_date": "2021-06-22",
      "last_synced_at": "2026-10-12T15:41:29.533Z",
      "location_count": 4,
      "location_summary": "Miami Springs, Florida • O'Fallon, Missouri • Saint Charles, Missouri + 1 more",
      "locations": [
        {
          "city": "Miami Springs",
          "state": "Florida"
        },
        {
          "city": "O'Fallon",
          "state": "Missouri"
        },
        {
          "city": "Saint Charles",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01760889"
    },
    {
      "nct_id": "NCT02659488",
      "title": "Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Binge Eating Disorder"
      ],
      "interventions": [
        {
          "name": "Lisdexamfetamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lindner Center of HOPE",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 55 Years · Female only"
      },
      "enrollment_count": 40,
      "start_date": "2015-09",
      "completion_date": "2017-12",
      "has_results": false,
      "last_update_posted_date": "2016-01-20",
      "last_synced_at": "2026-10-12T15:41:29.533Z",
      "location_count": 1,
      "location_summary": "Mason, Ohio",
      "locations": [
        {
          "city": "Mason",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02659488"
    },
    {
      "nct_id": "NCT01070394",
      "title": "Effectiveness and Duration of Effect of Open Treatment in Attention Deficit Hyperactivity Disorder (ADHD) Patients Treated With Lisdexamfetamine Dimesylate(Vyvanse)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "LDX Treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 40,
      "start_date": "2010-02",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2018-04-03",
      "last_synced_at": "2026-10-12T15:41:29.533Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01070394"
    },
    {
      "nct_id": "NCT00919867",
      "title": "A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "SPD503",
          "type": "DRUG"
        },
        {
          "name": "VYVANSE",
          "type": "DRUG"
        },
        {
          "name": "SPD503 and VYVANSE",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 42,
      "start_date": "2009-06-24",
      "completion_date": "2009-07-30",
      "has_results": true,
      "last_update_posted_date": "2021-06-14",
      "last_synced_at": "2026-10-12T15:41:29.533Z",
      "location_count": 1,
      "location_summary": "Hackensack, New Jersey",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00919867"
    },
    {
      "nct_id": "NCT01291173",
      "title": "Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Binge Eating Disorder"
      ],
      "interventions": [
        {
          "name": "lisdexamfetamine dimesylate (SPD489)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 271,
      "start_date": "2011-05-10",
      "completion_date": "2012-01-30",
      "has_results": true,
      "last_update_posted_date": "2021-06-10",
      "last_synced_at": "2026-10-12T15:41:29.533Z",
      "location_count": 31,
      "location_summary": "Little Rock, Arkansas • Beverly Hills, California • La Jolla, California + 28 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01291173"
    },
    {
      "nct_id": "NCT00764868",
      "title": "Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "ADHD"
      ],
      "interventions": [
        {
          "name": "Lisdexamfetamine Dimesylate (LDX)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "13 Years to 17 Years"
      },
      "enrollment_count": 269,
      "start_date": "2008-11-13",
      "completion_date": "2010-04-22",
      "has_results": true,
      "last_update_posted_date": "2021-06-14",
      "last_synced_at": "2026-10-12T15:41:29.533Z",
      "location_count": 45,
      "location_summary": "Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 40 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "El Centro",
          "state": "California"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Wildomar",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00764868"
    },
    {
      "nct_id": "NCT01324024",
      "title": "Attention & Memory Impairments in Menopausal Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Symptomatic Menopause",
        "Cognitive Impairments"
      ],
      "interventions": [
        {
          "name": "Lisdexamfetamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 60 Years · Female only"
      },
      "enrollment_count": 35,
      "start_date": "2011-05",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2017-06-28",
      "last_synced_at": "2026-10-12T15:41:29.533Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01324024"
    },
    {
      "nct_id": "NCT01436175",
      "title": "SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "SPD489 (Lisdexamfetamine dimesylate) + Antidepressant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 1570,
      "start_date": "2012-02-27",
      "completion_date": "2014-03-27",
      "has_results": true,
      "last_update_posted_date": "2021-06-14",
      "last_synced_at": "2026-10-12T15:41:29.533Z",
      "location_count": 140,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 113 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Carson",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01436175"
    }
  ]
}